Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 5/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782593 | 0.69 | LMNA (0.46) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL21729163 | 0.69 | BACE1 (0.36) | LMNAMAPTPOLB | |
| SCHEMBL8356086 | 0.65 | NPC1 (0.41) | DGAT1CTSLLMNAMAPTPOLB | |
| SCHEMBL2705447 | 0.63 | CHRM5 (0.38) | PTGFRPTGESCHRM5MEN1LMNA | |
| SCHEMBL2257948 | 0.63 | NOS1 (0.46) | SIGMAR1MEN1MAPTKMT2AHTR3E | |
| SCHEMBL8489151 | 0.62 | GAA (0.40) | LMNAMAPTHSD11B1 | |
| Hydrochloric Acid SCHEMBL3241445 | 0.62 | NOS1 (0.50) | SIGMAR1HTTHTR3EHTR3BHTR3A | |
| SCHEMBL22884146 | 0.61 | CHRM5 (0.43) | DGAT1PTGESCHRM5MEN1LMNA | |
| SCHEMBL11879687 | 0.61 | HTR3E (0.53) | SIGMAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL25257539 | 0.60 | KDM4E (0.44) | PTGFRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2435410-A2 | LXR MODULATORS | Exelixis Patent Company LLC (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163081-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | DGAT1 428/4885PTGFR 530/4885PTGES 836/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | DGAT1 428/4885PTGFR 530/4885PTGES 836/4885 |
| US-20150299136-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | DGAT1 428/4885PTGFR 530/4885PTGES 836/4885 |
| US-20160280661-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | DGAT1 428/4885PTGFR 530/4885PTGES 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.